# US 2015/0104494 A1 · Methods for repair of ear canal tissue defects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104494 A1
- Document ID: US20150104494A1
- Status: Published application
- Kind: A1
- Application number: 14/514,309
- Filed: 2014-10-14
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Applicants: Ohio State Innovation Foundation; New Technologies Holding, Pte. Ltd.
- Inventors: James C. Oliver; Judi Appleman; Wei Chen; D. Bradley Welling
- Web page: https://patentgrep.com/patent/US20150104494A1

## CPC

- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 9/0046: {Ear}
- A61K 31/727: Heparin; Heparan
- A61L 27/222: {Gelatin}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61L 2300/414: Growth factors
- A61L 2300/42: Anti-thrombotic agents, anticoagulants, anti-platelet agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Disclosed herein are methods of repairing ear canal tissue defects by administering non-basic fibroblast growth factor (FGF) to the ear canal tissue defect. Also disclosed are delivery devices to administer said non-basic FGF.

## Claims

### Claim 1

A method for treating an ear canal tissue defect in a subject, the method comprising administering to the subject an amount effective of non-basic fibroblast growth factor (FGF) to treat the ear canal tissue defect.

### Claim 2 (depends on 1)

The method of claim 1, wherein the non-basic FGF comprises FGF-1 (SEQ ID NO: 1) or a fragment thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the non-basic FGF comprises a polypeptide sequence of amino acids 15-155 of SEQ ID NO: 1.

### Claim 4 (depends on 2)

The method of claim 2, wherein the non-basic FGF consists of a polypeptide sequence of amino acids 15-155 of SEQ ID NO: 1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ear canal tissue defect comprises a perforated tympanic membrane.

### Claim 6 (depends on 2)

The method of claim 2, wherein the non-basic FGF is administered to the perforated tympanic membrane.

### Claim 7 (depends on 6)

The method of claim 6, wherein the non-basic FGF is administered using a delivery device.

### Claim 8 (depends on 7)

The method of claim 7, wherein the delivery device is a gelatin sponge.

### Claim 9 (depends on 7)

The method of claim 7, wherein the delivery device further comprises heparin.

### Claim 10 (depends on 7)

The method of claim 7, wherein the delivery device comprises a covering material.

### Claim 11 (depends on 10)

The method of claim 10, wherein the covering material comprises a fibrin glue.

### Claim 12 (depends on 1)

The method of claim 1, wherein effective amount of non-basic FGF comprises between about 25 μg/mL and 100 μg/mL.

### Claim 13 (depends on 1)

The method of claim 1, further comprising creating a fresh wound at the site of defect before administering the non-basic FGF.

### Claim 14

A gelatin sponge coated or impregnated with a non-basic FGF.

### Claim 15 (depends on 14)

The gelatin sponge of claim 14, wherein the non-basic FGF comprises FGF-1 (SEQ ID NO: 1) or a fragment thereof.

### Claim 16 (depends on 15)

The gelatin sponge of claim 15, wherein the non-basic FGF consists of a polypeptide sequence of amino acids 15-155 of SEQ ID NO: 1.

### Claim 17 (depends on 14)

The gelatin sponge of claim 14, wherein the gelatin sponge is impregnated with between about 25 μg/mL and about 100 μg/mL non-basic FGF.

### Claim 18 (depends on 14)

The gelatin sponge of claim 14, wherein the gelatin sponge further comprises heparin.

### Claim 19 (depends on 14)

The gelatin sponge of claim 14, wherein the gelatin sponge comprises a covering material.

### Claim 20 (depends on 19)

The gelatin sponge of claim 19, wherein the covering material comprises a fibrin glue.
